TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01

Tonix Pharmaceuticals Holding Corp. (the “Company”) announced the publication of a paper entitled “D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD effects in rats” (the “Publication”) in the European Journal of Pharmacology.  A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

The Company updated its corporate presentation, which it will present at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference on September 16, 2019, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 and 99.02 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm PRESS RELEASE   Tonix Pharmaceuticals Holding Corp. 8-K   Exhibit 99.01   Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology   NEW YORK,…
To view the full exhibit click here